Resmed Inc

NYSE:RMDUnited States

0353 GMT - Australia-listed drug and device makers may have to consider moving production due to potential tariffs by the incoming Trump administration, UBS analysts write in a note. They say that the likes of vaccine giant CSL, hearing-implant maker Cochlear, breath-tech provider ResMed and radiopharmaceutical developer Telix may have to consider the origin of various inputs and the location of production. Tariffs could motivate relocation of facilities to the U.S. but result in lower profitability for companies, they say. Protective-garment maker Ansell could benefit from tariffs on Chinese gloves, they add. (stuart.condie@wsj.com)

ResMed Announces Participation in the UBS Global Healthcare Conference

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA.